Meeting
2022 ASCO Annual Meeting
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
Authors
Sandro Pignata
Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Napoli, Italy
Sandro Pignata , Amit M. Oza , Geoff Hall , Beatriz Pardo , Radoslaw Madry , David Cibula , Jaroslav Klat , Ana Montes , Rosalind Glasspool , Nicoletta Colombo , Imre Pete , Ana Herrero , Marga Romeo , Rumyana Nedyalkova Ilieva , Constanta Timcheva , Massimo Di Maio , Alan Barnicle , Rosemary Taylor , Zahid Bashir , Andrew R. Clamp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02476968
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5519)
DOI
10.1200/JCO.2022.40.16_suppl.5519
Abstract #
5519
Poster Bd #
398
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.
First Author: Cara Amanda Mathews
Poster
2020 ASCO Virtual Scientific Program
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
First Author: Karen Anne Cadoo
Poster
2020 ASCO Virtual Scientific Program
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
First Author: Andres Poveda
Poster
2017 ASCO Annual Meeting
Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.
First Author: Jonathan A. Ledermann